CJC-1295 no DAC vs Tesamorelin: Which GHRH Analog?

## Introduction Among growth hormone-releasing hormone (GHRH) analogs in the published literature, two compounds dominate the research conversation: CJC-1295 no DAC and tesamorelin. Both are synthetic analogs of endogenous GHRH that stimulate growth hormone (GH) release from the anterior pituitary by acting on the GHRH receptor. Yet they were developed along different design philosophies, have produced different kinds of published data, and occupy different niches in GH-axis research. CJC-1295 no DAC (also called Modified GRF 1-29) is a tetrasubstituted analog of the 29-amino-acid GHRH fragment — a short-acting, pulsatile GHRH-receptor agonist with a reported half-life of approximately 30 minutes. It is a different product from CJC-1295 with DAC, which carries an albumin-binding moiety for multi-day circulation. Tesamorelin preserves the full 44-amino-acid sequence of native GHRH with a stabilizing N-terminal modification, and it carries one of the largest published clinical datasets of any GHRH analog — including Phase III trials in HIV-associated lipodystrophy. This guide compares CJC-1295 no DAC and tesamorelin head-to-head: their structures, mechanisms, pharmacokinetic profiles, the published literature behind each, and the research questions each is best suited to address. All discussion is research-framed; both are research compounds with defined regulatory status. ## CJC-1295 no DAC: The Short-Acting GHRH(1-29) Analog ### Structure and Design CJC-1295 no DAC is a synthetic analog of GHRH(1-29) — the biologically active 29-amino-acid fragment of native GHRH — with four amino acid substitutions that increase its resistance to enzymatic degradation: - **Position 2:** D-alanine for L-alanine — blocks cleavage by dipeptidyl peptidase-IV (DPP-IV), the primary route of native GHRH degradation. - **Position 8:** glutamine for glycine — reduces asparagine rearrangement and amide hydrolysis. - **Position 15:** alanine for glycine — designed to enhance receptor binding and bioactivity. - **Position 27:** leucine for methionine — prevents methionine oxidation during handling and storage. The resulting 29-residue peptide has molecular formula **C₁₅₂H₂₅₂N₄₄O₄₂** and molecular weight of approximately **3,367.9 g/mol**. Because it lacks any albumin-binding modification, CJC-1295 no DAC clears quickly — reported half-life of approximately 30 minutes — producing discrete, pulsatile GH release that more closely resembles the body's endogenous rhythm than sustained-release analogs. This makes it a tool for studying short-acting GHRH-receptor stimulation rather than depot-like pharmacology. > **Not the same product:** CJC-1295 with DAC is a different product — a maleimide-derived moiety attached at the C-terminus binds circulating albumin after administration, extending circulation to days. The DAC and no-DAC forms are not interchangeable in research. ### The Design Problem It Solves Native GHRH is degraded in plasma within minutes, which limits its usefulness as a research tool. Frohman and colleagues (1986) documented the rapid plasma degradation of native GHRH, establishing the design problem that stabilized analogs were built to solve: how to keep a GHRH-receptor agonist intact long enough to produce a measurable, reproducible GH pulse. > **Citation:** Frohman LA, Downs TR, Heimer EP, Felix AM. "Di-peptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma." *J Clin Invest*. 1986;78(4):906-913. [PubMed PMID: 3093533](https://pubmed.ncbi.nlm.nih.gov/3093533/) The D-alanine substitution at position 2 is the single most important of the four modifications. Soule and colleagues (1994) showed that D-Ala2-substituted GHRH analogs exhibit increased plasma half-life and decreased metabolic clearance in humans compared with native GHRH — the pharmacokinetic rationale behind the CJC-1295 no DAC scaffold. > **Citation:** Soule S, Bassett N, MacGillivray M, Yandle T. "Pharmacokinetics of a long-acting growth hormone-releasing hormone (GHRH) analogue." *J Clin Endocrinol Metab*. 1994;79(4):967-973. [PubMed PMID: 7962295](https://pubmed.ncbi.nlm.nih.gov/7962295/) Izdebski and colleagues (2002) further characterized potent stabilized analogs of human GHRH with enzymatic resistance, building the structure-activity evidence base for tetrasubstituted designs like CJC-1295 no DAC. > **Citation:** Izdebski J, Pinski J, Horvath JE, Halmos G, Groot K, Schally AV. "Synthesis and biological evaluation of potent new analogues of growth hormone-releasing hormone (GH-RH)." *J Pept Res*. 2002;60(4):217-231. [PubMed PMID: 12148777](https://pubmed.ncbi.nlm.nih.gov/12148777/) ### Research Profile In research settings, CJC-1295 no DAC is frequently studied in combination with ghrelin-receptor agonists (such as ipamorelin) to investigate dual-pathway GH stimulation — see our [CJC-1295 vs Ipamorelin comparison](/insights/cjc-1295-vs-ipamorelin). Its short-acting, pulsatile profile makes it suited to experiments where investigators want a defined GH pulse with rapid return to baseline, rather than sustained elevation. ## Tesamorelin: The Full-Length GHRH Analog ### Structure and Design Tesamorelin takes a different design approach. Rather than truncating to the 1-29 fragment, tesamorelin preserves the complete 44-amino-acid sequence of native human GHRH(1-44) and adds a trans-3-hexenoic acid group to the N-terminus. This N-terminal modification is the key to its pharmacology: it protects the peptide from cleavage by dipeptidyl peptidase-IV, the enzyme that degrades native GHRH within minutes, thereby extending its half-life while keeping the molecule's interaction with the GHRH receptor structurally close to the native hormone. Because tesamorelin stimulates endogenous GH release through the native receptor pathway rather than supplying GH directly, it preserves the body's own pulsatile GH secretion pattern and the intact hypothalamic-pituitary feedback axis — a property documented across its trial program. ### Published Findings Tesamorelin has one of the most extensive published datasets of any GHRH analog. The pivotal program evaluated the compound in HIV-infected adults with abdominal fat accumulation (lipodystrophy), a population with treatment-associated central adiposity. The landmark multicenter, randomized, placebo-controlled trial by Falutz and colleagues (2007) found that 26 weeks of daily tesamorelin decreased visceral fat and improved lipid profiles in HIV-infected patients with treatment-associated central fat accumulation. Importantly, no significant differences were observed in glycemic measures between treatment and placebo groups. > **Citation:** Falutz J, Allas S, Kotler D, et al. "Metabolic effects of a growth hormone-releasing factor in patients with HIV." *N Engl J Med*. 2007;357:2359-2370. [PubMed PMID: 18057338](https://pubmed.ncbi.nlm.nih.gov/18057338/) A follow-up randomized placebo-controlled trial with a safety extension (Falutz et al., 2010) further evaluated tesamorelin's effects on abdominal fat accumulation in HIV-infected patients, extending the evidence base for the compound's metabolic research profile. > **Citation:** Falutz J, Potvin D, Mamputu JC, Assaad H, Zoltowska M, Michaud SE, et al. "Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension." *J Acquir Immune Defic Syndr*. 2010;53(3):311-322. [PubMed PMID: 20101189](https://pubmed.ncbi.nlm.nih.gov/20101189/) For a deeper review of tesamorelin's structure and literature, see our [What Is Tesamorelin? research guide](/insights/what-is-tesamorelin). ## Head-to-Head Comparison | Feature | CJC-1295 no DAC | Tesamorelin | |---|---|---| | **Target receptor** | GHRH receptor (anterior pituitary) | GHRH receptor (anterior pituitary) | | **Base structure** | GHRH(1-29) fragment, tetrasubstituted | Full-length GHRH(1-44) | | **Key modification** | Four residue substitutions (D-Ala2, Gln8, Ala15, Leu27) | N-terminal trans-3-hexenoic acid group | | **Molecular weight** | ~3,368 g/mol | ~5,136 g/mol | | **Half-life** | ~30 minutes (short-acting) | Extended vs native GHRH; daily administration in trials | | **GH release pattern** | Discrete pulsatile pulses with rapid return to baseline | Preserved physiological pulsatility | | **Largest published dataset** | GHRH-analog pharmacology and structure-activity literature | Phase III randomized trials (HIV lipodystrophy program) | | **Primary research focus** | Pulsatile GH-axis pharmacology; dual-pathway studies with ghrelin agonists | Metabolic and body-composition research; visceral adiposity models | | **Common research pairings** | Ipamorelin, GHRP compounds (dual-pathway GH studies) | Studied as a standalone GHRH analog | ## Key Differences **Design philosophy.** CJC-1295 no DAC optimizes for a stabilized short pulse: four substitutions that resist enzymatic degradation without changing the duration paradigm — the peptide still clears in about half an hour, producing a defined GH pulse. Tesamorelin optimizes for fidelity: it keeps the full native 44-amino-acid GHRH sequence and makes a minimal N-terminal change to resist degradation, staying structurally closer to the endogenous hormone. **Evidence base.** The two compounds have been studied in different contexts. CJC-1295 no DAC's published record sits within the GHRH-analog pharmacology and structure-activity literature — enzymatic-resistance studies, receptor-binding work, and dual-pathway combination research. Tesamorelin's record centers on outcomes — large randomized trials measuring body-composition and metabolic endpoints in defined patient populations. Neither dataset directly substitutes for the other. **GH secretion dynamics.** CJC-1295 no DAC produces short, discrete GH pulses with rapid return to baseline — a pulsatile paradigm suited to experiments that need a defined stimulation window. Tesamorelin's profile is characterized in the literature as preserving physiological pulsatility with the body's own feedback mechanisms intact. **Research pairing conventions.** In the literature, CJC-1295 no DAC is frequently studied alongside ghrelin-receptor agonists to investigate synergistic GH release through two complementary pathways. Tesamorelin is more commonly studied as a standalone intervention, reflecting its clinical-trial heritage. ## Which Is Studied for What? **CJC-1295 no DAC is the more common choice in research focused on:** - Pulsatile GHRH-receptor pharmacology and structure-activity relationships - Short-acting GH pulse models with rapid return to baseline - Dual-pathway GH stimulation studies (paired with ipamorelin or GHRP compounds) - Comparative GHRH-analog enzymology and receptor binding **Tesamorelin is the more common choice in research focused on:** - Metabolic and body-composition endpoints - Visceral adiposity and lipid-metabolism models - GHRH-receptor signaling with near-native hormone structure - Long-term GH-axis modulation with preserved feedback Neither compound is approved for general use as a research chemical outside its defined regulatory status, and laboratory work should follow applicable regulations. ## Frequently Asked Questions ### Is CJC-1295 no DAC the same as CJC-1295 with DAC? No. They are different products with different pharmacokinetic profiles. CJC-1295 no DAC (Modified GRF 1-29) is a short-acting analog with a reported half-life of approximately 30 minutes. CJC-1295 with DAC carries an albumin-binding moiety that extends circulation to days. They are not interchangeable in research. ### Are CJC-1295 no DAC and tesamorelin the same thing? No. Both are synthetic GHRH analogs that stimulate GH release via the GHRH receptor, but they differ structurally: CJC-1295 no DAC is based on the tetrasubstituted GHRH(1-29) fragment, while tesamorelin preserves the full GHRH(1-44) sequence with an N-terminal stabilizing group. ### Which has more published clinical data? Tesamorelin has the larger published clinical dataset, including Phase III randomized controlled trials in HIV-associated lipodystrophy. CJC-1295 no DAC's published record sits in the GHRH-analog pharmacology and structure-activity literature. ### Do they preserve natural GH pulsatility? Both are reported to preserve pulsatile GH secretion in the published literature. CJC-1295 no DAC produces short, discrete pulses with rapid return to baseline; tesamorelin's profile is described as maintaining physiological pulse patterns with intact feedback regulation. ### Can CJC-1295 no DAC be studied in combination with other GH secretagogues? Yes. CJC-1295 no DAC is frequently studied alongside ghrelin-receptor agonists such as ipamorelin to investigate combined stimulation of the GHRH and ghrelin pathways. This dual-pathway approach is a recurring theme in GH-axis research literature. ## Conclusion CJC-1295 no DAC and tesamorelin represent two distinct answers to the same design problem: how to make a GHRH analog that survives long enough to be useful. CJC-1295 no DAC answers with four stabilizing substitutions that protect the 1-29 fragment from enzymatic degradation while keeping a short, pulsatile profile. Tesamorelin answers with a minimal modification to the full native hormone that preserves receptor fidelity. The published literature reflects these choices — pharmacology and structure-activity studies for CJC-1295 no DAC, outcomes-focused trial programs for tesamorelin. For laboratories selecting a GHRH analog for GH-axis research, the decision rests on the experimental question: pulsatile stimulation paradigms and dual-pathway combination designs point toward CJC-1295 no DAC; metabolic endpoints and near-native receptor signaling point toward tesamorelin. In both cases, verify ≥99% purity by HPLC, mass spectrometry identity confirmation, and a batch-specific Certificate of Analysis from an accredited laboratory. --- **Internal link suggestions:** - Product: [CJC-1295 no DAC 10MG](/product/cjc-1295-no-dac-10mg) - Product: [Tesamorelin 10MG](/product/tsm-10mg-tesa) - Related guide: [What Is Tesamorelin?](/insights/what-is-tesamorelin) - Related comparison: [CJC-1295 vs Ipamorelin](/insights/cjc-1295-vs-ipamorelin) For laboratory research use only. Not for human or veterinary use.